

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-4. (Canceled)

Claim 5. (Currently amended): A method for the treatment or prophylaxis of organ or tissue transplant rejection ~~or for the prolongation of graft survival~~ in a subject ~~in need thereof~~, comprising administering to ~~said a subject in need thereof~~ an effective amount of an agent selected from the group consisting of 3-(1-methyl-1H-indol-3-yl)-4-[1-((1-pyridin-2-ylmethyl)-piperidin-4-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, or 3-(1-methyl-1H-indol-3-yl)-4-[1-(piperidin-4-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, and a pharmaceutically acceptable salt, hydrate or solvate thereof.

Claims 6-14. (Canceled)

Claim 15. (Previously Presented): The method of claim 5, further comprising administering to said subject at least one additional agent selected from an immunosuppressant and an immunomodulatory drug.

Claim 16. (Previously Presented) The method of claim 15, wherein said at least one additional agent is cyclosporine A, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, mycophenolic acid or a salt thereof, mycophenolate mofetil, or a monoclonal antibody to CD25.

Claim 17. (Currently amended) A method for the prophylaxis of graft-versus-host disease in a subject ~~in need thereof~~, comprising administering to ~~said a subject in need thereof~~ an effective amount of an agent selected from the group consisting of 3-(1-methyl-1H-indol-3-yl)-4-[1-((1-pyridin-2-ylmethyl)-piperidin-4-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, or 3-(1-methyl-1H-indol-3-yl)-4-[1-(piperidin-4-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, and a pharmaceutically acceptable salt, hydrate or solvate thereof.

Claim 18. (Previously Presented): The method of claim 17, further comprising administering to said subject at least one additional agent selected from an immunosuppressant and an immunomodulatory drug.

Claim 19. (Previously Presented) The method of claim 18, wherein said at least one additional agent is cyclosporine A, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, mycophenolic acid or a salt thereof, mycophenolate mofetil, or a monoclonal antibody to CD25.

Claim 20. (New) A method for the prolongation of graft survival in a subject, comprising administering to a subject in need thereof an effective amount of an agent selected from the group consisting of 3-(1-methyl-1H-indol-3-yl)-4-[1-((1-pyridin-2-ylmethyl)-piperidin-4-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, or 3-(1-methyl-1H-indol-3-yl)-4-[1-(piperidin-4-yl)-1H-indol-3-yl]-pyrrole-2,5-dione, and a pharmaceutically acceptable salt, hydrate or solvate thereof.

Claim 21. (New): The method of claim 17, further comprising administering to said subject at least one additional agent selected from an immunosuppressant and an immunomodulatory drug.

Claim 22. (New) The method of claim 18, wherein said at least one additional agent is cyclosporine A, rapamycin, 40-O-(2-hydroxyethyl)-rapamycin, mycophenolic acid or a salt thereof, mycophenolate mofetil, or a monoclonal antibody to CD25.